CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
July 15, 2020
 CCTG investigators are contributing to COVID-19 research by developing and leading innovative, cutting-edge clinical trials to support patients with cancer. Read More |
|
|
 The CCTG Trialblazers raised $7200 as part of the Canadian Cancer Society's Relay For Life "At Home" event. Read More |
 Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Read More |
CO.26 Primary Publication and Other Recent PublicationsPublished: July 15, 2020Category: Publications  There were four recent publications, including the primary publication for CCTG CO.26: A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies. Read More |
|
|
June 24, 2020
Dr. Tim Whelan - 2020 Recipient of the CCTG Founder's Award - Dr. Joseph Pater Excellence in Clinical Trials ResearchPublished: June 24, 2020Category: News  CCTG is very pleased to announce that Dr. Tim Whelan is the 2020 recipient of the CCTG Founder's Award - Dr. Joseph Pater Excellence in Clinical Trials Research. This award honours an investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer. This individual's research has provided techniques, information or concepts that will direct the future of the oncology research community and CCTG. Read More |
Dr. Dan Renouf - 2020 Recipient of the Dr. Ralph Meyer Phase III Young Investigator AwardPublished: June 24, 2020Category: News  CCTG is very pleased to announce that Dr. Dan Renouf has been awarded the CCTG Dr. Ralph Meyer Phase III Program Young Investigator Award. This award honours young investigators who have contributed significantly on CCTG phase III projects with CCTG Disease Site Committees, Endpoint Committees, or Working Groups. “I’m very honored to both be nominated for and to receive this award. The mentorship provided to me by many members within CCTG is very much appreciated," says Dr. Renouf. Read More |